O'Grady J G, Williams R
Schweiz Med Wochenschr. 1986 Apr 26;116(17):541-4.
We describe our experience in the treatment of acute liver failure in 620 patients who developed grade 3 or 4 encephalopathy between 1973 and June 1985. The principal aetiologies were paracetamol-induced hepatic necrosis, viral hepatitis, halothane hepatitis and idiosyncratic drug reactions. Cerebral oedema is a major cause of death in these patients and is most effectively treated with mannitol (20%). Renal failure occurs in between 30% and 75% of cases, depending on aetiology, and is most effectively managed by haemodialysis. Electrolyte and acid-base abnormalities are common. Haemodynamic abnormalities encountered include a high cardiac output, low peripheral vascular resistance, hypotension and venodilatation. Assisted mechanical ventilation is frequently required to treat hypoxia caused by pneumonia, atelectasis, haemorrhage and oedema. A coagulopathy is always present but coagulation factors and platelets are given only when the patient is clinically bleeding. These patients are prone to sepsis and this is a significant cause of death. Hypoglycaemia is common and must be actively and frequently sought. The use of charcoal haemoperfusion has been associated with improved survival, especially when it is started during the grade 3 phase of encephalopathy. Recently survival figures of between 47% and 60% have been achieved for patients with paracetamol-induced liver failure and hepatitis A and B. However the figure for non A non B hepatitis and halothane- and drug-induced liver failure are disappointing at around 15% and liver transplantation is being explored as a treatment option in these patients.
我们描述了1973年至1985年6月期间620例出现3级或4级肝性脑病的急性肝衰竭患者的治疗经验。主要病因包括对乙酰氨基酚引起的肝坏死、病毒性肝炎、氟烷性肝炎和特异质性药物反应。脑水肿是这些患者死亡的主要原因,用甘露醇(20%)治疗最为有效。肾衰竭发生率在30%至75%之间,取决于病因,血液透析是最有效的治疗方法。电解质和酸碱异常很常见。所遇到的血流动力学异常包括高心输出量、低外周血管阻力、低血压和静脉扩张。经常需要辅助机械通气来治疗由肺炎、肺不张、出血和水肿引起的缺氧。凝血功能障碍始终存在,但仅在患者临床出血时才给予凝血因子和血小板。这些患者容易发生败血症,这是一个重要的死亡原因。低血糖很常见,必须积极频繁地查找。使用活性炭血液灌流可提高生存率,尤其是在肝性脑病3级阶段开始时。最近,对乙酰氨基酚引起的肝衰竭以及甲型和乙型肝炎患者的生存率达到了47%至60%。然而,非甲非乙型肝炎以及氟烷和药物引起的肝衰竭患者的生存率约为15%,令人失望,目前正在探索肝移植作为这些患者治疗选择。